Menu
GWAS Study

Exome array analysis of rare and low frequency variants in amyotrophic lateral sclerosis.

Dekker AM, Diekstra FP, Pulit SL et al.

30976013 PubMed ID
GWAS Study Type
7350 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

DA
Dekker AM
DF
Diekstra FP
PS
Pulit SL
TG
Tazelaar GHP
VD
van der Spek RA
VR
van Rheenen W
VE
van Eijk KR
CA
Calvo A
BM
Brunetti M
DP
Damme PV
RW
Robberecht W
HO
Hardiman O
MR
McLaughlin R
CA
Chiò A
SM
Sendtner M
LA
Ludolph AC
WJ
Weishaupt JH
PJ
Pardina JSM
VD
van den Berg LH
VJ
Veldink JH
Chapter II

Abstract

Summary of the research findings

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects 1 in ~350 individuals. Genetic association studies have established ALS as a multifactorial disease with heritability estimated at ~61%, and recent studies show a prominent role for rare variation in its genetic architecture. To identify rare variants associated with disease onset we performed exome array genotyping in 4,244 cases and 3,106 controls from European cohorts. In this largest exome-wide study of rare variants in ALS to date, we performed single-variant association testing, gene-based burden, and exome-wide individual set-unique burden (ISUB) testing to identify single or aggregated rare variation that modifies disease risk. In single-variant testing no variants reached exome-wide significance, likely due to limited statistical power. Gene-based burden testing of rare non-synonymous and loss-of-function variants showed NEK1 as the top associated gene. ISUB analysis did not show an increased exome-wide burden of deleterious variants in patients, possibly suggesting a more region-specific role for rare variation. Complete summary statistics are released publicly. This study did not implicate new risk loci, emphasizing the immediate need for future large-scale collaborations in ALS that will expand available sample sizes, increase genome coverage, and improve our ability to detect rare variants associated to ALS.

4,244 European ancestry cases, 3,106 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

7350
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
Germany, Netherlands, Belgium, Republic of Ireland, Italy, Spain
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.